ArticleOpen veterinary journal2026
Rare stability in dogs with myxomatous mitral valve disease: Clinical observations of loop diuretic withdrawal after congestive heart failure.
Article in Open veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myxomatous mitral valve disease (MMVD) is a common cause of congestive heart failure (CHF) in small-breed dogs. Clinical observations suggest that discontinuation of loop diuretics may be feasible in a subset of dogs with MMVD and CHF. Aim: To characterize dogs with MMVD-related CHF that achieved stability following loop diuretic withdrawal and to investigate potential contributing factors. Methods: We retrospectively analyzed 3,055 canine medical records of dogs diagnosed with MMVD (2012-2022) from the National Chung Hsing University Veterinary Medical Teaching Hospital database. Dogs considered stable and not requiring diuretic administration for at least 1 year after CHF diagnosis were included. Results: Six dogs (5 Maltese and 1 Toy Poodle) with a median age of 8.5 years and a median weight of 3.18 kg met the inclusion criteria. These dogs achieved stability after a median treatment duration of 675 days (range: 77-917 days) and were followed up for a period of 386-1,572 days. The presence of azotemia, radiographic evidence of reduced heart size, and evidence of long-term clinical stability supported diuretic tapering. All cardiac medications were discontinued in three dogs, while the remaining three continued pimobendan-based therapy. Conclusion: CHF secondary to MMVD in dogs can stabilize in rare instances without lifelong diuretic administration. These observations suggest that reversible or transient factors may contribute to the initial presentation of CHF in selected cases. Regular cardiac and renal assessments may help in identifying suitable candidates for diuretic adjustment when concurrent systemic conditions, such as azotemia, pose a limiting side effect despite sustained clinical stability or in rare instances of prolonged clinical stability without CHF signs. This approach facilitates individualized CHF management and improves the quality of life of both pets and their owners.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.